Surgical Robot Developer TransEnterix Will Not Test Device In Humans; Hopes For Market Launch In 2015

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TransEnterix will not have to test its surgical robot in humans before filing for approval with FDA, meaning it hopes to sell the medical device as early as 2015.

“This is what we were hoping for, and this was a good outcome for us,” says Todd Pope, CEO of TransEntererix (NYSE MKT: TRXC), which employs more than 100 workers.

Help employers find you! Check out all the jobs and post your resume.

Back to news